Translation







INTERNATIONAL PRELIMINARY EXAMINATION REPORT


(PCT Article 36 and Rule 70)

Applicant's or agent's file reference A21679M	FOR FURTHER ACTION SeeNotification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)						
International application No.	International filing date (day/i	month/year)	Priority date (day/month/year)				
PCT/JP03/00251	15 January 2003 (15	5.01.03)	16 January 2002 (16.01.02)				
International Patent Classification (IPC) or national classification and IPC A61K 31/192, 47/38, A61P 3/06, 3/10							
Applicant KOWA COMPANY, LTD.							
This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.							
2. This REPORT consists of a total of	sheets, includi	ing this cover sl	heet.				
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of sheets.							
3. This report contains indications rela	ating to the following items:						
I Basis of the report	Basis of the report						
II Priority	Distriction						
III Non-establishment	of opinion with regard to novel	ty, inventive ste	ep and industrial applicability				
IV Lack of unity of in	vention						
V Reasoned statemen	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
Certain documents	cited						
V1	VI Certain documents cited						
'	VII Certain defects in the international application						
VIII Certain observations on the international application							
D. 6.1	T	-61	Cal.:				
Date of submission of the demand		Date of completion of this report					
15 January 2003 (15.01.03)		19	May 2003 (19.05.2003)				
Name and mailing address of the IPEA/JP		Authorized officer					
Facsimile No.	Telep	hone No.					

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

Intern	al application No.
I	PCT/JP03/00251

I. Basis	of the report
1. With	regard to the elements of the international application:*
\boxtimes	the international application as originally filed
	the description:
-	pages, as originally filed
İ	pages, filed with the demand
	pages, filed with the letter of
	the claims;
	nages
1	pages, as originally filed pages, as amended (together with any statement under Article 19
	pages, as amonded (together with any statement under Article 19
İ	pages, filed with the letter of
	the drawings:
	, as virginity invo
	, mod whit the demand
	, met witt de letter of
L] t	he sequence listing part of the description:
	pages, as originally filed
	pages, filed with the demand
	pages, filed with the letter of
the in	regard to the language, all the elements marked above were available or furnished to this Authority in the language in which iternational application was filed, unless otherwise indicated under this item. The elements were available or furnished to this Authority in the following language which is:
	the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
H	the language of publication of the international application (under Rule 48.3(b)).
لــا	the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).
3. With prelin	regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international ninary examination was carried out on the basis of the sequence listing:
Ц	contained in the international application in written form.
Ц	filed together with the international application in computer readable form.
Ц	furnished subsequently to this Authority in written form.
Ц	furnished subsequently to this Authority in computer readable form.
	The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
L	The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4.	The amendments have resulted in the cancellation of:
į	the description, pages
ļ	the claims, Nos.
I	the drawings, sheets/fig
5. 🔲 🥫	This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
* Replacing this and 70	sement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to report as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16 0.17).
	placement sheet containing such amendments must be referred to under item 1 and annexed to this report.



v.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1.	Statement					
	Novelty (N)	Claims	1-4	YES		
	٠	Claims		NO NO		
	Inventive step (IS)	Claims	1-4	YES		
		Claims		NO		
	Industrial applicability (IA)	Claims	1-4	YES		
		Claims		NO		

2. Citations and explanations

Document 1: JP 10-510515 A

Document 2: JP 5-952 A

The inventions set forth in claims 1-4 are novel and involve an inventive step. Document 1 discloses 2,2dichloro-12-(4-chlorophenyl)dodecanoic acid useful as a therapeutic agent for diabetes mellitus, and indicates that for practical medicinal use of said compound various substances can be included as a solid carrier; however, it does not disclose or suggest the use of croscarmellose in order to improve the stability of the aforementioned 2,2dichloro-12-(4-chlorophenyl)dodecanoic acid. Document 2 discloses medicinal compositions containing torasemide wherein storage stability is improved by including hydroxypropyl cellulose and croscarmellose; however, it does not mention or suggest that croscarmellose which acts as a stabilizer in said medicinal preparations is equally effective in raising the stability of 2,2-dichloro-12-(4chlorophenyl) dodecanoic acid, which is the active ingredient in the inventions in the present application.